Immatics, a Germany-based cancer immunotherapy spinout from University of Tübingen, secured $58m in a series E round yesterday that featured pharmaceutical firm Amgen.
Life sciences investment firm Dievini Hopp Biotech, venture capital firm Wellington Partners, AT Impf and unnamed existing investors also participated in the round.
Founded in 2000, Immatics has created an antigen discovery platform called XPresident, which generates T-cell therapies from peripheral blood cells. T-cells are a part of the body’s immune system and a key component of…
